Brain Perfusion in Pantothenate Kinase-associated Neurodegeneration (PKAN)

Pantothenate Kinase-associated Neurodegeneration (PKAN) Clinical Trial

Official title:

Brain Perfusion in Pantothenate Kinase-Associated Neurodegeneration (PKAN)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01838018
• Other study ID #: 8777
• Status: Completed
• Start date: April 2013
• Est. completion date: January 2018

Study information

• Verified date: May 2018
• Source: Oregon Health and Science University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to learn whether blood flow in the brain is normal in people with pantothenate kinase-associated neurodegeneration (PKAN). Specifically, preliminary data suggest a region of the brain called the globus pallidus (GP), a key region affected by PKAN, may have reduced blood flow. Standard MRI and perfusion scanning techniques will be used to learn about cerebral blood flow in the globus pallidus and compare it to blood flow in other brain regions as well as to healthy controls.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 10
• Est. completion date: January 2018
• Est. primary completion date: October 2017
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 7 Years to 75 Years

Eligibility

Inclusion Criteria:

• diagnosis of PKAN confirmed by MRI and gene testing

• able to undergo MRI for approximately 1 hour without sedation

Exclusion Criteria:

• deep brain stimulators or other conditions that warrant avoidance of a strong magnetic field

• previous reaction to gadolinium (Gd) contrast agent

• acute or chronic kidney dysfunction

• pregnant and/or nursing at time of study

Related Conditions & MeSH terms

• Nerve Degeneration
• Pantothenate Kinase-Associated Neurodegeneration
• Pantothenate Kinase-associated Neurodegeneration (PKAN)

Locations

Country	Name	City	State
United States	Oregon Health & Science University	Portland	Oregon

Sponsors (3)

Lead Sponsor	Collaborator
Susan J. Hayflick	Oregon Clinical and Translational Research Institute, Oregon Health and Science University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	ASL-derived cerebral blood flow(CBF)	The unit of analyses will be the subject and the primary comparison will be the globus pallidus CBF between PKAN and healthy controls.	Single MRI

External Links

•   Link